

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
Sheet	G1	of	G1	Application Number	09/525,797
				Filing Date	03/15/2000
				First Named Inventor	Athanasius A. Anagnostou
				Group Art Unit	1642
				Examiner Name	Susan Ungar
				Attorney Docket Number	5218-39B

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Urushizaki, I. <u>Domain of Chemotherapy</u> , 10(6):1031-1037 (1994)	Partial
	2.	Anagnostou et al., "Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells", <u>Proc. Natl. Acad. Sci. USA</u> , 87(15):5978-5982 (1990)	
	3.	Fujioka et al., "Effects of recombinant erythropoietin on kidney cancer cell growth and tumor angiogenesis", <u>Autologous Blood Transfusion</u> , 8(1):46-50 (1995)	Partial
	4.	Nagai, T., "Effects of rHuEPO on cellular proliferation and endothelin-1 production in cultured endothelial cells", <u>J. of Japanese Soc. Of Nephrology</u> , 36(3):194-200 (1994)	Partial
	5.	Japanese Office Action corresponding to Japanese Patent Application No. 513794/1998 mailed August 28, 2007.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	08/18/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.